Abattis Bioceuticals Corp  

(Public, CNSX:ATT)   Watch this stock  
Find more results for CNSX:FLU
0.000 (0.00%)
Feb 27 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.09 - 3.10
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS     -
Shares 85.10M
Beta     -
Inst. own     -


355 Burrard St Suite 1000
+1-604-5386650 (Phone)
+1-604-8881519 (Fax)

Website links


Abattis Bioceuticals Corp, formerly Abattis Biologix Corporation, is a Canada-based company. On April 16, 2009, the Company entered into an agreement with PRB Pharmaceuticals, Inc. (PRB) and Pacific Bio-Pharmaceuticals, Inc. (Pacific Bio) for the purchase of their interest in patents and intellectual property related to anti viral products, which are designed to prevent avian influenza in humans and poultry. Effective April 7, 2014, Abattis Bioceuticals Corp acquired 51% interest in Phytalytics LLC. In May 2014, the Company, through its subsidiary Abattis Bioceuticals International Inc, raised its interest to 60% from 26%, by acquiring a 34% stake in Instant Payment Systems LLC.

Officers and directors

Mike Withrow President, Chief Executive Officer, Director
Rene David Chief Financial Officer, Chief Operating Officer
Guy P. Dancosse QC Independent Director
Terence Fealey Ph.D. Independent Director
Age: 66
Douglas J. Sorocco Independent Director